JDS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Journal of Dairy Science Vol. 78 No. 9 2086-2095
© 1995 by American Dairy Science Association ®
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Eenennaam, A. L.
Right arrow Articles by Guterbock, W. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Eenennaam, A. L.
Right arrow Articles by Guterbock, W. M.

Financial Analysis of Alternative Treatments for Clinical Mastitis Associated with Environmental Pathogens

A. L. van Eenennaam 1, I. A. Gardner 1, J. Holmes 1, L. Perani 1, R. J. Anderson 1, J. S. Cullor 1, and W. M. Guterbock 1

1 University of California, Davis 95616

For two large California dairy herds with twice daily milking, 171 infected quarters of lactating cows with mild clinical mastitis were randomly assigned to one of three treatment groups. Group A (50 cows) was treated with 62.5 mg of intramammary amoxicillin every 12 h for three milkings. Group C (50 cows) was treated with 200 mg of intramammary cephapirin every 12 h for two milkings. Group O (71 cows) was treated with 100 U of intramuscular oxytocin every 12 h for three milkings. Clinical cure rates did not differ among treatment groups. The cost per episode of clinical mastitis was higher ($54.47) for group C than for groups A ($38.53) or O ($34.88). Group O had a higher incidence of relapse (41%), and a greater percentage of group O cows (65%) experienced an additional mastitic event in the enrolled lactation than did cows in groups A and C. Treatment had no effect on the mean number of nonsalable milkings (24.7) associated with mastitis in the lactation interval subsequent to enrollment on the trial. Twenty-two percent of the cows accrued more than 30 nonsalable milkings and produced 55% of the total nonsalable milkings associated with mastitis. There was no treatment effect on total milk production, fat production, or time to removal of the enrolled cows from the herd.

Key Words: antibiotics • mastitis treatment • environmental pathogen • cost

Submitted on December 2, 1994
Accepted on March 28, 1995




This article has been cited by other articles:


Home page
 J DAIRY SCIHome page
H. W. Barkema, Y. H. Schukken, and R. N. Zadoks
Invited Review: The role of cow, pathogen, and treatment regimen in the therapeutic success of bovine Staphylococcus aureus mastitis.
J Dairy Sci, June 1, 2006; 89(6): 1877 - 1895.
[Abstract] [Full Text] [PDF]

Home page
 J DAIRY SCIHome page
S. J. LeBlanc, K. D. Lissemore, D. F. Kelton, T. F. Duffield, and K. E. Leslie
Major advances in disease prevention in dairy cattle.
J Dairy Sci, April 1, 2006; 89(4): 1267 - 1279.
[Abstract] [Full Text] [PDF]

Home page
 J DAIRY SCIHome page
J. R. Roberson, L. D. Warnick, and G. Moore
Mild to Moderate Clinical Mastitis: Efficacy of Intramammary Amoxicillin, Frequent Milk-Out, a Combined Intramammary Amoxicillin, and Frequent Milk-Out Treatment Versus No Treatment
J Dairy Sci, March 1, 2004; 87(3): 583 - 592.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American Dairy Science Association ®.